Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

benzinga.com/m-a/25/11/48836647/day-one-biopharma-expands-oncology-pipeline-with-285-million-mersana-buyout

Day One Biopharmaceuticals (NASDAQ:DAWN) on Thursday agreed to acquire Mersana Therapeutics Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers.
DAWN is among today’s weakest performers. Get the…

This story appeared on benzinga.com, 2025-11-13 15:15:16.
The Entire Business World on a Single Page. Free to Use →